Johnson & Johnson (JNJ) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 13, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Johnson & Johnson (JNJ), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Johnson & Johnson, analysts forecast revenue rising from $93.76B in 2025 to $135.29B in 2030; the average estimate for 2030 earnings per share is $17.55; with published estimates ranging from $17.29 to $17.86; 18 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Johnson & Johnson (JNJ) forecast — frequently asked questions
What is the analyst price target for Johnson & Johnson?
Analysts covering Johnson & Johnson (JNJ) have a consensus price target of $285.31, 0.8% above the current price of $283.07. Published targets range from $260.00 to $320.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Johnson & Johnson's earnings?
The average analyst estimate for Johnson & Johnson (JNJ) earnings per share in 2030 is 17.55, with individual estimates between 17.29 and 17.86.
How much revenue is Johnson & Johnson expected to make?
Analysts forecast Johnson & Johnson (JNJ) revenue of $135.29B in 2030, based on 17 published estimates.
How many analysts cover JNJ?
18 analysts contribute estimates for Johnson & Johnson (JNJ). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - General stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.